The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Jet2 swings to loss; Hyve Group sees busiest quarter

Thu, 08th Jul 2021 11:38

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Jet2 PLC - Yeadon, England-based airline and package holiday operator - Swings to a pretax loss of GBP369.9 million in the year ended March 31 from a profit of GBP147.7 million a year prior. Revenue sinks to GBP395.4 million from GBP3.58 billion. Single sector passengers flown comes in at 1.3 million, falling sharply from 14.6 million the year before. "Extensive restrictions on international travel imposed by the UK Government, meant our aircraft fleet was fully grounded for approximately 29 weeks of the financial year and operated with a significantly reduced programme when flying was permitted," says company. Does not declare a final dividend, unchanged from last year, given "the ongoing impact of Covid-19". This leaves shareholder's pockets empty for the year, compared to a total payout of 3.0 pence a year ago. "Group performance for the financial year ending March 31, 2022 is very much dependent on the level of flying permitted for the remainder of summer 2021 and performance in the second half of the financial year, periods for which we still have limited visibility. Unsurprisingly given the continuing short-term uncertainty, customers are booking significantly closer to departure for summer 2021; and, although bookings to date for [this coming winter] are satisfactory, they have slowed more recently given the ongoing speculation around international travel," says company.

----------

Hyve Group PLC - London-based exhibitions and conferences organiser - Says the third quarter to end June "has been the group's busiest trading quarter since the Covid-19 pandemic began". Says 18 in-person events ran over the quarter, bringing the total number for the year to date to 28. The increased number of events reflects the continued momentum across the group's Eastern markets, primarily Russia, China, Turkey and Ukraine, company says. "[The third quarter] is traditionally a strong trading period for the group and it is extremely encouraging that Hyve has successfully run more events in the quarter than in the entirety of the first half. Many of the group's key markets in the East have been open for a number of months now and, combined with the continued pace of the vaccine rollout in our Western markets, this gives the group continued confidence when looking ahead to the final quarter of [the 2021 financial year] and beyond," CEO Mark Shashoua says.

----------

Fuller, Smith & Turner PLC - London-based pub and hotel company - Reports pretax loss of GBP57.8 million in the year to March 27, swinging from a profit of GBP8.4 million a year ago. Revenue plummets to GBP73.2 million from GBP316.0 million due to the enforced closure of social businesses throughout the year. "No full year dividend proposed in light of pandemic impact on trading performance, but intention to return to progressive dividend policy at the appropriate time," says company. Did not pay a final dividend a year prior. "The boom in staycations and desire to get back out with friends has led to strong trading in parts of our estate - particularly Cotswold Inns & Hotels and our rural pubs with rooms - and there is an incredibly busy season to come with numerous weddings and a high level of advance bookings," says Chief Executive Simon Emeny. Aims at "sustainable returns for the long term".

----------

Equals Group PLC - London-based payments and e-banking firm - Says revenue for the first half to June 30 is up 21% to GBP16.7 million from GBP13.8 million a year ago, "despite the continued absence of meaningful travel-related activity". "The hard work undertaken on both product development and cost restructuring over the last twelve months has really paid off as can be seen from these excellent revenues for [the second half of] 2021. Given the growth trajectory, we remain highly confident about the revenue prospects for second half of the year," says CEO Ian Taylor.

----------

ReNeuron Group PLC - Pencoed, Wales-based developer of cell-based therapeutics - Posts pretax loss for the year to end March of GBP13.4 million, narrowing from GBP13.9 million. Revenue falls sharply to GBP257,000 from GBP6.1 million. Revenue mostly comes from royalties from non-therapeutic licensing activities and income from research collaboration activities. Research development costs fall 41% to GBP9.5 million from GBP16.3 million. "Our decision in 2020 to focus the Company's resources on our retinal disease programme and our exosome and iPSC platforms has resulted in significantly lower operating costs, as reflected in the results for the year," says CEO Olav Hellebo. Looks forward to "data-driven potential value inflection points" over the next 12 months.

----------

JPMorgan Global Core Real Assets Ltd - real estate, transportation and infrastructure investor - Posts net asset value per share at February 28 of 87.9p, tumbling 9.1% from 96.8p a year ago. Pretax loss widens to GBP12.7 million from GBP4.7 million. Annual payout stands at 3.25p per share. Last year, the firm paid a maiden interim dividend of 0.75p per share. "The directors intend to maintain the current level of dividend payments and review the level of dividend cover in the coming quarter...Your board is hopeful that over the longer term the success of the underlying businesses into which we invest will facilitate a steadily growing level of dividends." says company. Says it has weathered the pandemic and the only headwind is "the current strength of pound sterling relative to most foreign currencies, an issue which many regard as a 'high quality problem'".

----------

Yu Group PLC - Nottingham, England-based supplier of gas, electricity and water to the UK business market - Says it has made a "very strong" start to the year and expects the positive momentum to continue. In the six months to end June, revenue is expected to increase 42% to GBP65.0 million from GBP45.9 million a year ago. Says it is confident it will meet market expectations for the year. Expects to report a strong earnings before interest, tax, depreciation and amortisation performance for the year, with further improvement into 2022 as "the group benefits from high scale benefits and its digital roll out".

----------

Mpac Group PLC - Coventry, England-based packaging company - Says the strong momentum in the second half of 2020 has continued into the first half of 2021. In the first half of 2021, order intake has been "significantly above" the Covid-impacted first half of 2020. Says it is comfortable with current full year market expectations. "I am pleased to report a strong start to 2021 across all regions. The outlook is positive based on trends in new prospects and customer investment discussions, and we enter the second half of 2021 with both a strong order book and a developing prospect pipeline and we remain confident that we can leverage the One Mpac operating model to deliver sustainable profitability," says CEO Tony Steels.

----------

InnovaDerma PLC - London-based developer of beauty, personal care and life science products - Says despite Covid-19 headwinds, revenues for the year have performed broadly in line with expectations. Expects revenue for year to end June of no less than GBP10.2 million, down 23% from GBP13.3 million last year. Believes that future prospects will improve once Covid-19 restrictions are lifted and social norms return. Expects to return to profitability for the year to end June 2022.

----------

Surface Transforms PLC - Liverpool-based maker of carbon‐ceramic automotive brake discs - Says revenue in first half of 2021 grows 34% to GBP1.2 million from GBP900,000 a year prior, exceeding managements' original expectations. Says revenue is expected to increase further in the final quarter of 2021 following the start of production on the multi-year original equipment manufacturing contracts.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
29 Nov 2019 16:07

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
23 Oct 2019 15:50

ReNeuron presents new data on CTX stem cell platform

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Wednesday that new data relating to its CTX stem cell platform was being presented at the 27th Annual Congress of the European Society of Gene and Cell Therapy in Barcelona.

Read more
23 Oct 2019 09:32

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

Read more
2 Oct 2019 15:15

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

Read more
21 Aug 2019 11:49

ReNeuron boosts scientific advisory board with three appointments

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced the appointment of professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its scientific advisory board on Wednesday.

Read more
14 Aug 2019 15:35

ReNeuron's New Cardiff University Venture Gets Research Grant

(Alliance News) - ReNeuron Group PLC on Wednesday said a new venture with Cardiff University has secured a UK government grant to research and develop new treatments for hard-to-target disorders a

Read more
14 Aug 2019 11:16

ReNeuron enters grant-funded partnership with University of Cardiff

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group is partnering with the University of Cardiff under a new grant-funded collaboration utilising its exosome-based drug delivery technology platform, it announced on Wednesday.

Read more
16 Jul 2019 12:16

ReNeuron Secures Patents For Its Exosome Technology Platform

(Alliance News) - ReNeuron Group PLC on Tuesday said it has expanded its intellectual property estate via the grant of patents, covering its exosome technology platform.The cell-based said

Read more
11 Jul 2019 11:36

ReNeuron Annual Loss Narrows On Finance Income And Licence Fee

(Alliance News) - ReNeuron Group PLC on Thursday said its loss narrowed in its most recent financial year after it received an exclusivity fee and increased finance income.Shares in were at

Read more
14 Jun 2019 15:49

ReNeuron wins 'Breakthrough of the Year' at European Mediscience Awards

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has won the 'Breakthrough of the Year' award at the 2019 European Mediscience Awards, it announced on Friday.

Read more
8 May 2019 11:19

ReNeuron Expects Annual Results In Line With Views After Progress

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday said it expects its annual results to be in line with the board's expectations as it made progress on several clinical cell-based also

Read more
8 May 2019 08:53

ReNeuron advances blindness and stroke therapy candidates

(Sharecast News) - Therapeutics outfit ReNeuron continued to trade in line with expectations throughout its recently wrapped up trading year, advancing both its human retinal progenitor cell therapy candidate and its CTX cell therapy candidate.

Read more
26 Apr 2019 12:09

ReNeuron upbeat on early data from retinitis pigmentosa trials

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced updated positive preliminary data in its ongoing phase 1 and 2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP), on Friday.

Read more
26 Apr 2019 09:58

ReNeuron Reports Positive Test Results For Blindness Treatment Therapy

LONDON (Alliance News) - ReNeuron Group PLC on Friday reported positive trial results for its human retinal progenitor cell therapy candidate for treating blindness-causing disease retinitis in up

Read more
11 Apr 2019 18:24

DIRECTOR DEALINGS: ReNeuron Chair And Other Board Members Buy Shares

LONDON (Alliance News) - ReNeuron Group PLC said a number of directors purchased shares on Thursday, including Non-Executive Chair John Berriman who bought 80,000 shares at 225 pence Thursday, in

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.